References
- Bachmann G. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:312–16
- Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002;57:385–409
- Cauley JA, Robbins J, Chen Z, et al.; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAm Med Assoc 2003;290:1729–38
- De Leo V, la Marca A, Morgante G, et al. Random-ized control study of the effects of raloxifene on serum lipids and homocysteine in older women. AmJ Obstet Gynecol 2001;184:350–3
- Setacci C, la Marca A, Agricola E, et al. Effects of the selective estrogen receptor modulator, raloxifene, on carotid artery pulsatility index in postmenopausal women. Am J Obstet Gynecol. 2002;186:832–5
- Davies GC, Huster WJ, Shen W, et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogens in postmenopausal women. Menopause 1999;6:188–95
- Barret-Connor E. Raloxifene: risks and benefits. Ann NY Acad Sci 2001;949:295–303
- Silberstein SD, De Lignieres B. Migraine, menopause and hormonal replacement therapy. Cephalalgia 2000; 20:214–21
- Kenemans P, Van Unnik GA, Mijatovik V, et al. Perspectives in hormone replacement therapy. Maturitas 2001;38:541–8
- La Vecchia C. Estrogens and progestins in hormone replacement therapy in menopause. Recent Prog Med 2001;92:209–12
- Thomas AM, Hickey M, Fraser IS. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod 2000;15:7–17
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Melis GB, Gambacciani M, Cagnacci A, et al. Effects of the dopamine antagonist Veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988;72:688–92
- David A, Don R, Tajchner G, et al. Veralipride: alter-native antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988;158:1107–15
- Riggs BL, Hartmann LC. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618–29
- Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 1999;34:65–73.